CMS Signals Possible Rewrite of Nursing Home Antipsychotic Measure After Years of Provider Pushback

Washington, District of Columbia — Federal regulators are taking a fresh look at one of nursing homes’ most contentious quality measures, reopening a fight over antipsychotic use that providers say has long punished clinically appropriate care along with the bad actors.

The Centers for Medicare & Medicaid Services said it is reviewing the antipsychotic quality measure with the goal of supporting clinically indicated use while still discouraging inappropriate prescribing. The agency said it remains committed to evidence-based quality measures and transparency for residents and families, but it did not say when any changes might be made.

The review matters because the measure helps shape public-facing ratings and has carried real consequences for operators. Nursing homes have cut antipsychotic use sharply since 2012, yet many providers argue the current framework still fails to separate inappropriate chemical restraint from legitimate treatment decisions made for residents with severe dementia-related symptoms and other behavioral health needs.

Providers say the current metric misses context

Industry groups said they have recently seen signs that CMS may be more open to revisiting the policy than in prior years. One concern is that the measure can penalize facilities when a physician determines an antipsychotic is necessary, even after non-drug interventions have already been tried. Another is that newata inputs have made facility performance harder to predict and manage.

That debate has been building for years. As SCJ recently reported in its coverage of the fight over nursing home antipsychotic ratings, operators and pharmacists have argued that the current scoring system can blur the line between overuse and justified prescribing. The new CMS review suggests that argument is finally getting a harder look inside the agency.

According to industry reports, some advocates want CMS to rely more heavily on MDS-based information and clearer physician documentation standards so surveyors and families can better distinguish between appropriate and inappropriate use. Supporters of a rewrite say that would give consumers a more accurate picture while protecting residents who genuinely benefit from carefully monitored treatment.

Congressional pressure added momentum

The issue gained added traction after The Washington Post reported that congressional report language accompanying a recent federal spending bill urged CMS to better distinguish between appropriate and inappropriate prescribing in nursing homes. CMS told industry sources, however, that its review was already underway before that language appeared.

For operators, the stakes go beyond one measure. Antipsychotic scores can influence referrals, public perception and internal quality strategy. If CMS changes course, even modestly, the move could reshape how facilities document care, defend clinical decisions and manage reputational risk tied to the Five-Star system.

For now, providers are watching for details. CMS has acknowledged the tension. The next question is whether the agency will make a technical tweak — or finally redraw a policy line that nursing homes say has been overdue for years.